Oracon

07/01/1984 - " Oracon was found in detailed study to be strongly associated with subsequent risk for cancer, while other sequentials and combination pills were found to reduce the risks. "
03/06/1980 - " If an OC, like Oracon, emphasizes the estrogenic component, promotion of cancer can be the result. "
01/01/1988 - " These results, which are at variance with those reported for users of other sequential brands (mainly Oracon), suggest that prolonged use of Ortho-Novum SQ does not enhance the risk of endometrial cancer in premenopausal women having no additional risk factors for the development of this type of neoplasia."
07/01/1984 - "Cancer is the presumed complication of oral contraceptive (OC) use that is of greatest concern to the public, although with the exception of cancer of the endometrium, which was linked to 1 specific type of sequential preparation, Oracon, there is no convincing evidence linking OCs and cancer. "
03/06/1980 - "These associations suggest that development of neoplasia in the endometrium can be extremely sensitive to hormonal factors: if an oral contraceptive, like Oracon, emphasizes the estrogenic component, promotion of cancer can result; if like combined preparations, the contraceptive emphasizes the progestational component, protection against cancer can result. "

03/06/1980 - " Yet the study did show that women who took the sequential drug Oracon have a risk of endometrial cancer that is appreciably higher than that of women who did not take OCs. "
05/01/1980 - " The increased risk of endometrial cancer among users of sequentials was due to 1 preparation, Oracon. "
03/06/1980 - " It is likely that the use of Oracon predisposed women to the development of endometrial cancer. "
01/01/1991 - " Endometrial cancer risk seems to be decreased, except for the sequential contraceptive Oracon which is associated with increased risk. "
01/01/1988 - " These results, which are at variance with those reported for users of other sequential brands (mainly Oracon), suggest that prolonged use of Ortho-Novum SQ does not enhance the risk of endometrial cancer in premenopausal women having no additional risk factors for the development of this type of neoplasia."

08/01/1976 - "Non-atypical adenomatous hyperplasia was found in 13.5% of 111 biopsies obtained from long-term, predominantly black, users of Oracon. "
06/01/1976 - "The progression of endometrial changes from benign proliferation to cystic hyperplasia and adenomatous hyperplasia accompanied by varying degrees of anaplasia in young women exposed to Oracon for long periods of time is significant. "

04/07/1969 - "A request for suggestions in management of a 38-year-old woman in good health suffering breakthrough bleeding after 3 years of therapy on ethinyl estradiol plus dimethisterone with ethinyl estradiol (Oracon) for the control of heavy menstrual flow elicited the following response. "

07/01/1984 - " Oracon was different from other sequentials in that it contained a large amount of estrogen, 100 mcg of ethinyl estradiol, with only a weak progestin, 25 mg of dimethisterone, too little to reverse estrogen-induced endometrial hyperplasia. "